TABLE 4

Antimicrobial activity of arbekacin and comparator agents when tested against multidrug-resistant organisms

Organism (no. of isolates tested) and antimicrobial agentaMIC (μg/ml)% S/% I/% Rb
50%90%RangeCLSIEUCAST
ESBL-producing E. coli (33)
    Arbekacin2160.25–>512—/—/——/—/—
    Amikacin4321–>51281.8/9.1/9.169.7/12.1/18.2
    Gentamicin8>1280.12–>12848.5/6.0/45.545.5/3.0/51.5
    Tobramycin325120.25–>51227.3/12.1/60.624.2/3.0/72.8
    Ceftazidime165120.25–>51242.4/0.0/57.615.2/27.2/57.6
    Imipenem0.250.50.12–0.5100.0/0.0/0.0100.0/0.0/0.0
ESBL -producing K. pneumoniae (38)
    Arbekacin0.5160.25–16—/—/——/—/—
    Amikacin2>5120.5–>51284.2/5.3/10.568.4/15.8/15.8
    Gentamicin41280.25–25650.0/21.1/28.944.7/5.3/50.0
    Tobramycin81280.25–>51226.3/23.7/50.021.1/6.2/73.7
    Ceftazidime64>5121–>51221.1/2.6/76.315.8/2.6/81.6
    Imipenem0.120.5≤0.06–0.5100.0/0.0/0.0100.0/0.0/0.0
KPC-producing K. pneumoniae (40)
    Arbekacin8160.25–>512—/—/——/—/—
    Amikacin16640.5–>51242.5/32.5/25.030.0/12.5/57.5
    Gentamicin41280.25–>12850.0/5.0/45.042.5/7.5/50.0
    Tobramycin32640.25–>51225.0/0.0/75.025.0/0.0/75.0
    Ceftazidime2655121–>5127.5/10.0/82.50.0/12.8/79.5
    Imipenem264≤0.06–2560.0/5.0/95.05.0/27.5/67.5
CAZ-R E. cloacae (21)
    Arbekacin0.510.25–1—/—/——/—/—
    Amikacin220.5–4100.0/0.0/0.0100.0/0.0/0.0
    Gentamicin0.510.25–12890.5/0.0/9.590.5/0.0/9.5
    Tobramycin110.25–3290.5/4.8/4.890.5/0.0/9.5
    Ceftazidime6412832–2560.0/0.0/100.00.0/0.0/100.0
    Imipenem0.510.12–1100.0/0.0/0.0100.0/0.0/0.0
CAZ-R C. freundii (20)
    Arbekacin0.510.5–16—/—/——/—/—
    Amikacin241–6495.0/0.0/5.095.0/0.0/5.0
    Gentamicin1320.5–>12880.0/0.0/20.080.0/0.0/20.0
    Tobramycin1320.5–25675.0/0.0/25.075.0/0.0/25.0
    Ceftazidime12812816–2560.0/0.0/100.00.0/0.0/100.0
    Imipenem0.510.25–1100.0/0.0/0.0100.0/0.0/0.0
IMI-R P. aeruginosa (31)
    Arbekacin4640.5–>512—/—/——/—/—
    Amikacin82561–>51264.5/9.7/25.854.8/9.7/35.5
    Gentamicin16>1280.5–>12838.7/6.5/54.838.7/0.0/61.3
    Tobramycin32>1280.25–51241.9/3.3/54.841.9/0.0/58.9
    Ceftazidime64>5122–12832.3/6.4/61.332.3/6.4/61.3
    Imipenem162568–>5120.0/0.0/100.00.0/0.0/100.0
IMI-R A. baumannii (50)
    Arbekacin8320.5–>512—/—/——/—/—
    Amikacin128>5121–>51228.0/10.0/62.020.0/8.0/72.0
    Gentamicin128>1280.25–>12814.0/2.0/84.014.0/0.0/86.0
    Tobramycin32640.5–>51224.0/12.0/64.024.0/0.0/76.0
    Ceftazidime128>5120.25–>51210.0/2.0/88.0—/—/—
    Imipenem641288–2560.0/0.0/100.00.0/0.0/100.0
MRSA (70)
    Arbekacin110.12–4—/—/——/—/—
    Amikacin8161–25690.0/7.1/2.968.6/21.4/10.0
    Gentamicin1640.12–>12868.6/0.0/31.468.9/0.0/31.4
    Tobramycin22560.5–>51251.4/0.0/48.644.3/7.1/18.6
  • a ESBL, extended spectrum β-lactamase, CAZ-R, ceftazidime-resistant (MIC, ≥16 μg/ml); IMI-R, imipenem-resistant (MIC, ≥8 μg/ml); MRSA, methicillin-resistant S. aureus (14).

  • b Criteria as published by the CLSI (2014) (14). —, no criteria available.